Last quarter (Q ), Alterola Biotech's total revenue was $―, a decrease of ― from the same quarter last year. In Q, Alterola Biotech's net income was $-2.01M. See Alterola Biotech’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Mar 23	Mar 22	Mar 21	Sep 20	Sep 19
Total Revenue	-	-	-	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 2.51M	$ 1.90M	$ 6.35M	$ 309.50K	$ 329.51K	$ 258.45K
Operating Income	$ -1.27M	$ -1.17M	$ -6.35M	$ -309.50K	$ -329.51K	$ -258.45K
Net Non Operating Interest Income Expense	$ 15.25K	-	-	$ 0.00	$ 0.00	$ -249.00
Other Income Expense	$ 19.43K	$ 347.36K	-	-	$ 79.00K	-
Pretax Income	$ -138.62K	$ -1.70M	$ -6.47M	$ -309.50K	$ -250.51K	$ -258.70K
Tax Provision	$ -255.82K	$ -154.52K	-	$ 0.00	$ 0.00	$ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -2.99M	$ -1.54M	$ -6.47M	$ -309.50K	$ -250.51K	$ -258.70K
Basic EPS	-	-	-	$ >-0.01	$ >-0.01	$ >-0.01
Diluted EPS	-	-	-	$ >-0.01	$ >-0.01	$ >-0.01
Basic Average Shares	-	-	-	$ 442.36M	$ 118.06M	$ 116.56M
Diluted Average Shares	-	-	-	$ 754.28M	$ 118.06M	$ 116.56M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 2.51M	$ 1.90M	$ 6.35M	$ 309.50K	$ 329.51K	$ 258.45K
Interest Expense	-	-	-	$ 0.00	$ 0.00	$ 249.00
Net Income From Continuing And Discontinued Operation	$ -3.47M	$ -1.74M	$ -6.47M	$ -309.50K	$ -250.51K	$ -258.70K
Normalized Income	$ 444.61K	-	-	$ -309.50K	$ -250.51K	$ -258.70K
EBIT	$ -153.87K	$ -1.70M	$ -6.47M	$ -309.50K	$ -250.51K	$ -258.45K
EBITDA	$ -153.87K	$ -1.70M	$ -6.47M	$ -309.50K	$ -250.51K	$ -258.45K

Currency in USD

Alterola Biotech Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing